A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer

被引：0
|
作者：
Bangyou Zuo
Xiaobo Yang
Xu Yang
Jin Bian
Junyu Long
Dongxu Wang
Cong Ning
Yanyu Wang
Ziyu Xun
Yunchao Wang
Xin Lu
Yilei Mao
Xinting Sang
Haitao Zhao
机构：
[1] Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC),Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital
来源：
Cancer Immunology, Immunotherapy | 2022年 / 71卷
关键词：
Gallbladder cancer; PD-1; Lenvatinib; PD-L1 expression;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1889 / 1896
页数：7
相关论文
共 50 条
  • [41] Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients
    Yang, Xu
    Chen, Bowen
    Wang, Yanyu
    Wang, Yunchao
    Long, Junyu
    Zhang, Nan
    Xue, Jingnan
    Xun, Ziyu
    Zhang, Linzhi
    Cheng, Jiamin
    Lei, Jin
    Sun, Huishan
    Li, Yiran
    Lin, Jianzhen
    Xie, Fucun
    Wang, Dongxu
    Pan, Jie
    Hu, Ke
    Guan, Mei
    Huo, Li
    Shi, Jie
    Yu, Lingxiang
    Zhou, Lin
    Zhou, Jinxue
    Lu, Zhenhui
    Yang, Xiaobo
    Mao, Yilei
    Sang, Xinting
    Lu, Yinying
    Zhao, Haitao
    HEPATOLOGY INTERNATIONAL, 2023, 17 (03) : 709 - 719
  • [42] Outcomes of anti-PD1 antibodies for advanced melanoma in real-world population
    van Zeijl, M. C. T.
    Wouters, M. W. J. M.
    van den Eertwegh, A. J.
    Aarts, M. J.
    van Akkooi, A. C. J.
    van den Berkmortel, F. W. P. J.
    Franken, M. G.
    de Groot, J. W. B.
    Herbschleb, K. H.
    van der Hoeven, J. J. M.
    Hospers, G. A. P.
    Kapiteijn, E.
    Piersma, D.
    van Rijn, R. S.
    Suijkerbuijk, K. P. M.
    Ten Tije, A. J.
    Van der Veldt, A. A. M.
    Vreugdenhil, G.
    Haanen, J. B. A. G.
    ANNALS OF ONCOLOGY, 2018, 29
  • [43] Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients
    Xu Yang
    Bowen Chen
    Yanyu Wang
    Yunchao Wang
    Junyu Long
    Nan Zhang
    Jingnan Xue
    Ziyu Xun
    Linzhi Zhang
    Jiamin Cheng
    Jin Lei
    Huishan Sun
    Yiran Li
    Jianzhen Lin
    Fucun Xie
    Dongxu Wang
    Jie Pan
    Ke Hu
    Mei Guan
    Li Huo
    Jie Shi
    Lingxiang Yu
    Lin Zhou
    Jinxue Zhou
    Zhenhui Lu
    Xiaobo Yang
    Yilei Mao
    Xinting Sang
    Yinying Lu
    Haitao Zhao
    Hepatology International, 2023, 17 : 709 - 719
  • [44] PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma
    Ellebaek, Eva
    Khan, Shawez
    Bastholt, Lars
    Schmidt, Henrik
    Haslund, Charlotte Aaquist
    Donia, Marco
    Svane, Inge Marie
    EUROPEAN JOURNAL OF CANCER, 2024, 198
  • [45] Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis
    Cheon, Jaekyung
    Chon, Hong Jae
    Bang, Yeonghak
    Park, Neung Hwa
    Shin, Jung Woo
    Kim, Kang Mo
    Lee, Han Chu
    Lee, Jooho
    Yoo, Changhoon
    Ryoo, Baek-Yeol
    LIVER CANCER, 2020, 9 (05) : 613 - 624
  • [46] Real-world efficacy and safety of lenvatinib in Korean patients with advanced hepatocellular carcinoma: A multicenter retrospective analysis
    Cheon, J.
    Yoo, C.
    Bang, Y.
    Chon, H.
    Ryoo, B-Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1308 - S1308
  • [47] Anti-PD-1 therapy combined with chemotherapy or target therapy in patients with advanced biliary tract cancer in real-world clinical setting
    Sun, D.
    Ma, J.
    Han, C.
    Wang, J.
    Qian, Y.
    Chen, G.
    Li, X.
    Zhang, J.
    Song, J.
    Zhao, X.
    Cai, S.
    Hu, Y.
    ANNALS OF ONCOLOGY, 2018, 29 : 437 - 437
  • [48] Real-World Efficacy and Safety of Lenvatinib in Advanced or Recurrent Thymic Carcinoma: A Multicenter Retrospective Study in Japan
    Miyamoto, Satoshi
    Tsukaguchi, Akihiro
    Kuhara, Hanako
    Otsuki, Taiichiro
    Shiroyama, Takayuki
    Tamiya, Motohiro
    Tamiya, Akihiro
    Nishino, Kazumi
    Takeda, Yoshito
    Kijima, Takashi
    Okumura, Meinoshin
    Kumanogoh, Atsushi
    Mori, Masahide
    THORACIC CANCER, 2025, 16 (06)
  • [49] Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study
    Wang, Yunchao
    Yang, Xiaobo
    Wang, Yanyu
    Xue, Jingnan
    Zhang, Nan
    Yang, Xu
    Cong, Ning
    Zhang, Junwei
    Zhu, Chengpei
    Zhang, Longhao
    Hou, Xiaorong
    Zhao, Haitao
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (07) : 2197 - 2204
  • [50] Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study
    Yunchao Wang
    Xiaobo Yang
    Yanyu Wang
    Jingnan Xue
    Nan Zhang
    Xu Yang
    Ning Cong
    Junwei Zhang
    Chengpei Zhu
    Longhao Zhang
    Xiaorong Hou
    Haitao Zhao
    Cancer Immunology, Immunotherapy, 2023, 72 : 2197 - 2204
12345